Company: INDP
Filing Date: 2025-03-13
Form Type: POS AM
Source: 0001493152-25-010137
Chunk: 11

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: POS AM
Chunk 11
---
040 shares of common stock as the Advance Shares that that we have reserved for issuance and sale to YA as Advance Shares under the Purchase Agreement from time to time during the Commitment Period, subject to the restrictions and satisfaction of the conditions in the Purchase Agreement, if and when we determine to sell additional shares to YA under the Purchase Agreement.

YA has no right to require us to sell any shares to YA, but YA is obligated to make purchases of the Advance Shares as directed by us, subject to the restrictions and satisfaction of conditions set forth in the Purchase Agreement upon receipt of a notice sent by us to YA setting forth the number of shares that we desire to issue and sell to YA, or an Advance Notice. Actual sales of the Advance Shares to YA from time to time will depend on a variety of factors, including, among others, market conditions, the trading price of our shares and determinations by us as to the appropriate sources of funding for us and our operations. The purchase price of the Advance Shares that we may direct YA to purchase from time to time under the Purchase Agreement will be equal to 97% of the lowest of the three daily VWAPs during the three consecutive trading day period commencing on the date that we deliver any Advance Notice to YA, or the Pricing Period.

| 4 |

As of March 12, 2025, there were 14,429,244 shares of common stock outstanding, of which 12,857,209 shares were held by non-affiliates. If all of the 10,000,000 shares of common stock offered by YA under this prospectus were issued and outstanding, such shares would represent approximately 41% of the total number of shares of common stock outstanding and approximately 44% of the total number of outstanding shares of common stock held by non-affiliates, in each case as of March 12, 2025. The Purchase Agreement provides that we may sell up to an aggregate of $20.0 million of shares of common stock to YA. We have filed the registration statement that includes this prospectus so that we may issue and sell to YA up 10,000,000 shares of common stock from time to time from during the Commitment Period, subject to the restrictions and satisfaction of the conditions in the Purchase Agreement, through sales under the Purchase Agreement. Depending on the market prices of our shares at the time we elect to issue such shares to YA under the Purchase Agreement, we may need to sell more shares to YA than are offered under this prospectus